VVD-130850 is under clinical development by Vividion Therapeutics and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for Non-Hodgkin Lymphoma have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VVD-130850’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - VVD-130850 in Non-Hodgkin Lymphoma

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VVD-130850 overview

VVD-130850 is under development for treatment of solid tumor, advanced non-Hodgkin's lymphoma (NHL), non-small cell lung cancer and unspecified immunological disorders. It acts by targeting signal transducer and activator of transcription 3 (STAT3). It is administered through oral route. It is being developed based on chemoproteomics drug discovery technology platform.

See Also:

Vividion Therapeutics overview

Vividion Therapeutics, a subsidiary of Bayer AG, is a biotechnology company. Its lead programs target NRF2, STAT3 and WRN. The company’s drug discovery platform allows protein-drug interactions to be measured with extraordinary breadth and precision in native biological systems. Vividion Therapeutics’s approach expands the spectrum of therapeutic opportunities for small-molecule drugs. Its NRF2 used for the treatment of inflammation-induced tissue injury. The company operates offices in San Diego and serves across the US. Vividion Therapeutics is headquartered in San Diego, California, the US.

For a complete picture of VVD-130850’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.